SCM
TEVA icon

Saba Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Saba Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,216,000
Closed -$11.8M – 759
2021
Q3 		$11.8M Sell
1,216,000
-3,173,500
-72% -$29.7M 0.29% 70
2021
Q2 		$43.5M Buy
+4,389,500
New +$46.5M 1.24% 13
2019
Q4 		– Sell
-1,775,900
Closed -$12.2M – 101
2019
Q3 		$12.2M Buy
+1,775,900
New +$13.6M 0.57% 40

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Saba Capital Management's TEVA Position: Q2 2024 in Review

Saba Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 131,005 shares — an estimated $1.85M sold.

Saba Capital Management first reported a position in TEVA in Q3 2019 and held it in 7 quarters. The position peaked at $1.93M in Q3 2023. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Saba Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Saba Capital Management sold 131,005 Teva Pharmaceuticals shares in Q2 2024, an estimated $1.85M.
  • Saba Capital Management first reported a position in Teva Pharmaceuticals in Q3 2019 and held it in 7 quarters.
  • Saba Capital Management's Teva Pharmaceuticals position peaked at $1.93M in Q3 2023.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Saba Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.